The Breakdown of Preformed Peritoneal Advanced Glycation End Products by Intraperitoneal Alagebrium.
10.3346/jkms.2009.24.S1.S189
- Author:
Yong Kook LEE
1
;
Joon Yeop LEE
;
Jun Seup KIM
;
Ki Bum WON
;
Hyeok Joo KANG
;
Tae Jung JANG
;
Woo Taek TAK
;
Jeong Ho LEE
Author Information
1. Department of Internal Medicine, Dongguk University Medical Center, Gyeongju, Korea. jhlee@dongguk.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Advanced Glycation End Products;
Aminoguanidine;
Alagebrium;
Peritoneal Dialysis
- MeSH:
Animals;
Biological Transport;
Body Weight;
Cell Membrane/metabolism;
Glycosylation End Products, Advanced/*metabolism;
Guanidines/metabolism;
Immunohistochemistry/methods;
Male;
Peritoneal Dialysis/*methods;
Peritoneum/metabolism/*pathology;
*Permeability;
Rats;
Rats, Sprague-Dawley
- From:Journal of Korean Medical Science
2009;24(Suppl 1):S189-S194
- CountryRepublic of Korea
- Language:English
-
Abstract:
It has been demonstrated that inhibitors of advanced glycation end products (AGE), such as aminoguanidine, can suppress peritoneal AGE in rats on peritoneal dialysis (PD). However, it is unknown whether late administration of a putative crosslink breaker, alagebrium, could reverse peritoneal AGE. We therefore compared alagebrium with aminoguanidine in their ability to reverse peritoneal AGE in rats on PD. Male Sprague-Dawley rats were randomly divided into 3 groups: group I dialyzed with 4.25% glucose solution for all exchanges; group II dialyzed with 4.25% glucose solution containing aminoguanidine, and group III dialyzed with 4.25% glucose solution containing alagebrium for last 8 weeks of 12-week dialysis period. Dialysis exchanges were performed 2 times a day for 12 weeks. Immunohistochemistry was performed using a monoclonal anti-AGE antibody. One-hour PET was performed for comparison of transport characteristics. The immunolabelling of AGE in peritoneal membrane was markedly decreased in the alagebrium group. Consistent with this, the alagebrium group exhibited significantly higher D/Do glucose and lower D/P urea, suggesting low peritoneal membrane transport. But there were no significant differences between the control and the aminoguanidine group. These results suggest that the alagebrium may be the optimal therapeutic approach, compared with treatment with inhibitors of AGE formation, in rats on PD.
